SEC Comment Letter 0000000000-26-006619 to Tempest Therapeutics, Inc. (TPST)
Tempest Therapeutics, Inc.
Date: July 2, 2026 · CIK: 0001544227 · Accession: 0000000000-26-006619
AI Filing Summary & Sentiment
File numbers found in text: 333-297061
Letter
July 2, 2026 Matthew Angel Chief Executive Officer Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane, CA 94005 Re: Tempest Therapeutics, Inc. Registration Statement on Form S-3 Filed June 26, 2026 File No. 333-297061 Dear Matthew Angel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael J. Minahan, Esq.
Show Raw Text
July 2, 2026 Matthew Angel Chief Executive Officer Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane, CA 94005 Re: Tempest Therapeutics, Inc. Registration Statement on Form S-3 Filed June 26, 2026 File No. 333-297061 Dear Matthew Angel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael J. Minahan, Esq.